Barry P Flannelly has sold INCY and made no open-market buys since Oct 2016
EVP, GM US at Incyte Corporation
SEC CIK 0001615842 · Filings on SEC.gov ↗
Every filing
21 filings since Oct 2016, newest first
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
Incyte Corp
EVP, GM US
About Barry P Flannelly
Barry P. Flannelly is a person and a seasoned biopharmaceutical executive with more than 35 years of experience in the pharmaceutical and biotechnology industries.( He most recently served as Executive Vice President and General Manager, North America at Incyte, and an SEC filing in March 2025 identifies him as EVP & General Manager US.( Earlier in his career, he worked in oncology roles at Rhone-Poulenc Rorer (later Sanofi-Aventis), Novartis Pharmaceuticals, Abraxis Oncology, Onyx Pharmaceuticals, and Nektar Therapeutics, where he built sales and marketing organizations and helped lead commercial efforts for oncology products.(
Flannelly earned a Doctor of Pharmacy from the University of Maryland School of Pharmacy, an MBA from the University of Baltimore, and a Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy.( He has also been associated with Protara Therapeutics as a board member, reflecting his broader involvement in the biotechnology sector.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.